Stocks Health care GOSS
NASDAQ · Health careGossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. brought in $53.3M of revenue over the twelve months to June 30, 2026, up 32.4% from a year earlier. It posted a net loss of $125.2M. In fiscal 2025 capital spending exceeded operating cash flow by $171.3M. At June 30, 2026 it held $41.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Gossamer Bio, Inc.
- Net worth
- Gossamer Bio, Inc. has a market value (market cap) of $5.2B at the latest share price, and shareholders' equity of -$94M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $48.5M (-57.7% year on year), with a net loss of $170.4M. Over the 12 months to June 30, 2026: revenue $53.3M, net loss $125.2M.
- Cash flow
- In fiscal 2025 operations used $171.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Gossamer Bio, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Gossamer Bio, Inc. does
Gossamer Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GOSS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $48.5M | -$170.4M | -$0.75 | -$171.3M |
| 2024 | $114.7M | -$56.5M | -$0.25 | -$3.5M |
| 2023 | $0 | -$179.8M | -$1.18 | -$159.2M |
| 2022 | $0 | -$229.4M | -$2.71 | -$187.4M |
| 2021 | n/a | -$234M | -$3.13 | -$190.4M |
| 2020 | n/a | -$243.4M | -$3.55 | -$177.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where GOSS ranks in Health care
Latest SEC filings
What Gossamer Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026Activist stake changed SCHEDULE 13D/A
- September 28, 2026Other event 8-K
- September 23, 2026Other event 8-K
- September 16, 2026Proxy statement DEF 14A
- September 16, 2026
- September 11, 2026
- September 9, 2026Other event 8-K
- September 3, 2026Preliminary proxy statement PRE 14A
- September 3, 2026
- August 26, 2026
Insider trades
What the people running Gossamer Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 2, 2026 | Hasnain FaheemPresident & CEO, Director | Received as pay | 280,000 | - |
| January 2, 2026 | Christian WaageEVP, Tech Ops and Admin | Received as pay | 84,500 | - |
| January 2, 2026 | Giraudo BryanCOO/CFO | Received as pay | 115,750 | - |
| January 2, 2026 | Peterson CarynEVP, Regulatory Affairs | Received as pay | 84,500 | - |
| January 2, 2026 | Aranda RichardChief Medical Officer | Received as pay | 93,750 | - |
| January 2, 2026 | Smith Robert Paul JRChief Commercial Officer | Received as pay | 93,750 | - |
Who owns GOSS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| 683 Capital Management, LLC13G, passive with 2 related filers | 9.99% | June 11, 2026 |
| Context Capital Management, LLC13G, passive with 4 related filers | 9.9% | June 9, 2026 |
| DeepCurrents Investment Group LLC13G, passive with 3 related filers | 7.7% | June 11, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 6.3% | November 12, 2024 |
| D. E. Shaw & Co., L.L.C.13D, may seek influence with 3 related filers | 5.1% | September 28, 2026 |
| Opaleye Management Inc.13G, passive with 2 related filers | 5.1% | July 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 170 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| D. E. Shaw & Co., Inc. | 40,959,285 | +40,569,854 |
| 683 Capital Management, LLC | 39,198,868 | +34,198,868 |
| DeepCurrents Investment Group LLC | 37,665,073 | new |
| Context Capital Management, LLC | 28,946,459 | new |
| Worth Venture Partners, LLC | 25,017,881 | new |
| Kalehua Capital Management LLC | 22,298,726 | +4,590,593 |
| Aqr Capital Management LLC | 15,629,993 | +5,503,096 |
| Wolverine Asset Management LLC | 12,894,746 | new |
| Renaissance Technologies LLC | 11,629,896 | +10,412,028 |
| Vanguard Capital Management LLC | 9,416,023 | +21,430 |
| ARCH Venture Management, LLC | 8,055,916 | 0 |
| Barclays PLC | 7,832,522 | +4,766,716 |
| Octagon Capital Advisors LP | 7,750,000 | 0 |
| BlackRock, Inc. | 7,669,943 | -9,156,752 |
| Arrowstreet Capital, Limited Partnership | 7,573,388 | new |
| Two Sigma Investments, LP | 7,432,001 | +2,651,150 |
| Samsara Biocapital, LLC | 7,222,559 | 0 |
| Qube Research & Technologies Ltd | 7,065,756 | +2,147,993 |
| Corient Private Wealth LP | 5,632,698 | +1,647,315 |
| Siren, L.L.C. | 5,208,968 | 0 |
Insiders
6 insiders reported holding 3,024,928 shares in total, about $32.4M at the last price.
| Holder | Shares |
|---|---|
| Hasnain FaheemPresident & CEO, Director | 837,793 |
| Christian WaageEVP, Tech Ops and Admin | 814,061 |
| Aranda RichardChief Medical Officer | 463,106 |
| Giraudo BryanCOO/CFO | 389,737 |
| Smith Robert Paul JRChief Commercial Officer | 260,898 |
| Peterson CarynEVP, Regulatory Affairs | 259,333 |
Questions about GOSS
What does Gossamer Bio, Inc. do?
Gossamer Bio, Inc. is a company in the Health care sector, listed on NASDAQ as GOSS. Its shares trade on NASDAQ under the ticker GOSS.
What is Gossamer Bio, Inc.'s net worth?
Gossamer Bio, Inc. has a market value (market cap) of $5.2B at the latest share price, and shareholders' equity of -$94M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Gossamer Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $125.2M on revenue of $53.3M.
How much revenue does Gossamer Bio, Inc. make?
Over the twelve months to June 30, 2026 Gossamer Bio, Inc. reported revenue of $53.3M. That is 32.4% more than a year earlier.
When did Gossamer Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from September 28, 2026.
When is Gossamer Bio, Inc.'s next earnings report?
Gossamer Bio, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare GOSS with
Follow GOSS
Get an email when Gossamer Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Gossamer Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.